Michael D. Axelson

3.2k total citations · 1 hit paper
6 papers, 2.3k citations indexed

About

Michael D. Axelson is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Michael D. Axelson has authored 6 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Molecular Biology, 3 papers in Oncology and 2 papers in Pathology and Forensic Medicine. Recurrent topics in Michael D. Axelson's work include Genetic factors in colorectal cancer (2 papers), Colorectal Cancer Treatments and Studies (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). Michael D. Axelson is often cited by papers focused on Genetic factors in colorectal cancer (2 papers), Colorectal Cancer Treatments and Studies (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). Michael D. Axelson collaborates with scholars based in United States, Australia and Italy. Michael D. Axelson's co-authors include Andrew Hill, Scott Kopetz, Ray McDermott, Heinz‐Josef Lenz, Jayesh Desai, Thierry André, Monica V. Goldberg, Michael J. Overman, Rebecca A. Moss and Michael A. Morse and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Clinical Cancer Research.

In The Last Decade

Michael D. Axelson

6 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

2017 2.0k citations Michael J. Overman, Ray McDermott et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael D. Axelson United States	5	1.9k	811	447	399	396	6	2.3k
Michael A. Morse United States	13	1.8k 1.0×	650 0.8×	465 1.0×	432 1.1×	321 0.8×	24	2.1k
Ka Yeung Mark Wong Australia	11	1.7k 0.9×	780 1.0×	352 0.8×	354 0.9×	340 0.9×	17	1.9k
Fabio Gelsomino Italy	19	2.3k 1.3×	947 1.2×	394 0.9×	519 1.3×	494 1.2×	71	2.8k
Christian Borel France	23	1.2k 0.7×	324 0.4×	197 0.4×	496 1.2×	433 1.1×	78	1.9k
Leigh Marcus United States	12	1.1k 0.6×	358 0.4×	217 0.5×	488 1.2×	311 0.8×	18	1.6k
Eiji Shinto Japan	27	1.9k 1.0×	522 0.6×	140 0.3×	629 1.6×	863 2.2×	116	2.4k
Young Wha Koh South Korea	26	892 0.5×	343 0.4×	319 0.7×	563 1.4×	197 0.5×	82	1.7k
Kevin Norwood United States	22	1.3k 0.7×	363 0.4×	180 0.4×	504 1.3×	779 2.0×	38	1.8k
Shota Fukuoka Japan	14	1.5k 0.8×	350 0.4×	644 1.4×	553 1.4×	330 0.8×	65	1.9k

Countries citing papers authored by Michael D. Axelson

Since Specialization

Citations

This map shows the geographic impact of Michael D. Axelson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael D. Axelson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael D. Axelson more than expected).

Fields of papers citing papers by Michael D. Axelson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael D. Axelson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael D. Axelson. The network helps show where Michael D. Axelson may publish in the future.

Co-authorship network of co-authors of Michael D. Axelson

This figure shows the co-authorship network connecting the top 25 collaborators of Michael D. Axelson. A scholar is included among the top collaborators of Michael D. Axelson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael D. Axelson. Michael D. Axelson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Epstein, Caroline G., Alexandria M. Bobe, Joshua S. K. Bell, et al.. (2020). Real-world Evidence of Diagnostic Testing and Treatment Patterns in US Patients With Breast Cancer With Implications for Treatment Biomarkers From RNA Sequencing Data. Clinical Breast Cancer. 21(4). e340–e361. 10 indexed citations

2.

Overman, Michael J., Ray McDermott, Joseph L. Leach, et al.. (2017). Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. The Lancet Oncology. 18(9). 1182–1191. 1977 indexed citations breakdown →

3.

Overman, Michael J., Scott Kopetz, Ray McDermott, et al.. (2016). Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results.. Journal of Clinical Oncology. 34(15_suppl). 3501–3501. 109 indexed citations

4.

Axelson, Michael D., Ke Liu, Xiaoping Jiang, et al.. (2013). U.S. Food and Drug Administration Approval: Vismodegib for Recurrent, Locally Advanced, or Metastatic Basal Cell Carcinoma. Clinical Cancer Research. 19(9). 2289–2293. 140 indexed citations

5.

Refaai, Majed A., Theodore E. Warkentin, Michael D. Axelson, Karén Matevosyan, & Ravi Sarode. (2007). Delayed-onset heparin-induced thrombocytopenia, venous thromboembolism, and cerebral venous thrombosis: A consequence of heparin “flushes”. Thrombosis and Haemostasis. 98(11). 1139–1140. 31 indexed citations

6.

Axelson, Michael D., Mary A. Davis, Stephen P. Ethier, & Theodore S. Lawrence. (1999). HPV16-E7 Expression Causes Fluorodeoxyuridine-mediated Radiosensitization in SW620 Human Colon Cancer Cells. Neoplasia. 1(2). 177–182. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact